XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.21.2

Share-Based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Share-Based Compensation | 12. Share-Based Compensation On November 18, 2015, the Company’s Board of Directors adopted and approved the 2015 Equity Incentive Plan (the 2015 Plan), which authorized the Company to grant up to 223,424 ordinary shares in the form of incentive share options, nonstatutory share options, share appreciation rights, restricted share awards, restricted share units and other share awards. The types of share-based awards, including the rights, amount, terms, and exercisability provisions of grants are determined by the Company’s Board of Directors. The purpose of the 2015 Plan is to provide the Company with the flexibility to issue share-based awards as part of an overall compensation package to attract and retain qualified personnel. On May 18, 2017, the Company amended the 2015 Plan to increase the number of ordinary shares available for issuance under the 2015 Plan by 219,605 shares to 443,029 shares. On March 14, 2018, the Company’s Board of Directors adopted and approved the 2018 Equity Incentive Plan (the 2018 Plan), which became effective upon the execution and delivery of the underwriting agreement related to the Company’s IPO in May 2018. No further grants will be made under the 2015 Plan. The ordinary shares underlying any options that are forfeited, cancelled, repurchased or are otherwise terminated by the Company under the 2015 Plan will not be added back to the ordinary shares available for issuance. The 2018 Plan authorizes the Company to grant up to 1,018,459 ordinary shares in the form of incentive share options, nonstatutory share options, share appreciation rights, restricted share awards, restricted share units, performance share awards, performance cash awards and other share awards. The types of share-based awards, including the amount, terms, and exercisability provisions of grants are determined by the Company’s Board of Directors. The ordinary shares underlying any options that are forfeited, cancelled, repurchased or are otherwise terminated by the Company under the 2018 Plan will be added back to the ordinary shares available for issuance under the 2018 Plan. On December 5, 2018, pursuant to powers delegated to it by the Board of Directors of the Company, the Compensation Committee approved an increase in the number of ordinary shares available to be granted pursuant to the 2018 Plan by 4% of the total number of shares of the Company’s issued share capital on December 31, 2018, being 574,081 ordinary shares. On February 14, 2020, pursuant to powers delegated to it by the Board of Directors of the Company, the Compensation Committee approved, by written resolution, an increase of 594,758 ordinary shares to the number of ordinary shares available to be granted pursuant to the 2018 Plan, being just under 4% of the total number of the Company’s ordinary shares outstanding on December 31, 2019, in accordance with the terms of the 2018 Plan. On June 10, 2020, at the Company’s annual general meeting of shareholders, the shareholders approved and adopted an amended and restated 2018 Plan which, among other things includes an increase of 2,250,000 ordinary shares to the number of ordinary shares reserved for issuance under the 2018 Plan. On June 23, 2021, at the Company’s annual general meeting of shareholders, the shareholders approved an amendment to the amended and restated 2018 Plan to increase by 15,000,000 ordinary shares the number of ordinary shares reserved for issuance under the amended and restated 2018 Plan. Share Options The Company granted 13,621,412 and 64,840 share options to employees and directors during the nine months ended September 30, 2021 and 2020, respectively, under the 2018 Plan. There were 13,732,567 and 420,783 unvested employee options outstanding as of September 30, 2021 and September 30, 2020, respectively. Total expense recognized related to employee share options was $1,663 and $2,104 for the three and nine months ended September 30, 2021, respectively, and $259 and $922 for the three and nine months ended September 30, 2020, respectively. Total unamortized compensation expense related to employee share options was $22,385 and $1,722 as of September 30, 2021 and September 30, 2020, respectively, which is expected to be recognized over a remaining average vesting period of 3.68 years and 1.81 years as of September 30, 2021 and September 30, 2020, respectively. The range of assumptions that the Company used to determine the grant date fair value of employee and director options granted were as follows:
|  | Nine months ended
|  | September 30, 2021 |  | September 30, 2020
Volatility |  | 120 - 130% |  | 90.3% - 99.5%
Expected term in years |  | 5.5 - 6.25 |  | 5.5 - 6.25
Dividend rate |  | 0% |  | 0%
Risk-free interest rate |  | 0.90% - 1.32% |  | 0.18% - 0.78%
Share price |  | $0.56 - $2.01 |  | $1.68 - $2.03
Fair value of option on grant date |  | $0.50 - $1.75 |  | $1.27 - $1.52
The following table summarizes the number of options outstanding and the weighted-average exercise price as of September 30, 2021:
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life in Years |  |  | Aggregate Intrinsic Value (in thousands) |
Options outstanding December 31, 2020 |  |  | 953,377 |  |  | $ | 7.36 |  |  |  | 5.41 |  |  | $ | — |
Granted |  |  | 13,621,412 |  |  |  | 1.98 |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  |  |  |  |  |  |  |  |  |  |  |
Forfeited |  |  | — |  |  |  |  |  |  |  |  |  |  |  |  |
Expired |  |  | (303,392 | ) |  | $ | 8.54 |  |  |  |  |  |  |  |  |
Options outstanding September 30, 2021 |  |  | 14,271,397 |  |  | $ | 2.20 |  |  |  | 9.59 |  |  | $ | — |
Exercisable at September 30, 2021 (unaudited) |  |  | 538,830 |  |  | $ | 6.65 |  |  |  | 6.46 |  |  | $ | — |
Restricted Share Units (RSUs) The Company granted 1,345,328 RSUs to employees and directors during the nine months ended September 30, 2021. No RSUs were granted to employees and directors during the nine months ended September 30, 2020. The table below shows the number of RSUs outstanding covering an equal number of the Company’s ordinary shares and the weighted-average grant date fair value of the RSUs outstanding as of September 30, 2021:
|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value per Share |
RSUs outstanding December 31, 2020 |  |  | — |  |  |  |  |
Granted |  |  | 1,345,328 |  |  | $ | 1.60 |
Shares vested |  |  | (60,000 | ) |  | $ | 1.60 |
Forfeited |  |  | — |  |  |  |  |
RSUs outstanding September 30, 2021 |  |  | 1,285,328 |  |  | $ | 1.60 |
The fair value of the RSUs is determined on the date of grant based on the market price of the Company’s ordinary shares on that date. The fair value of RSUs is expensed ratably over the vesting period, which is generally one year for directors and two years for employees. Total expense recognized related to the RSUs was $304 and $668 for the three and nine months ended September 30, 2021, respectively, and $1 and $63 for the three and nine months ended September 30, 2020, respectively. Total unamortized compensation expense related to RSUs was $1,467 as of September 30, 2021, which is expected to be recognized over a remaining average vesting period of 1.35 years as of September 30, 2021. No RSUs, which are subject to certain performance-based vesting conditions (Performance RSUs), were awarded to employees or directors during the nine months ended September 30, 2021. The Company awarded 1,079,000 Performance RSUs to certain employees during the nine months ended September 30, 2020. The table below shows the number of Performance RSUs outstanding covering an equal number of the Company’s ordinary shares and the weighted-average grant date fair value of the Performance RSUs outstanding as of September 30, 2021:
|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value per Share |
Performance RSUs outstanding December 31, 2020 |  |  | 983,000 |  |  | $ | 2.20 |
Granted |  |  | — |  |  |  |  |
Shares vested |  |  | (629,500 | ) |  | $ | 2.01 |
Expired |  |  | (327,500 | ) |  | $ | 2.00 |
Performance RSUs outstanding September 30, 2021 |  |  | 26,000 |  |  |  |  |
The weighted average grant date fair value of Performance RSUs with a market condition was determined using the Monte Carlo simulation model. The fair value of Performance RSUs is expensed evenly over the vesting period. Due to the expiration of Performance RSUs during the three months ended September 30, 2021, a credit of $455 and $420 was recognized for the three and nine months ended September 30, 2021, respectively. Total expense recognized related to Performance RSUs was $590 and $1,648 for the three and nine months ended September 30, 2020, respectively. All RSUs were fully expensed as of September 30, 2021. Total unamortized compensation expense related to Performance RSUs was $381 as of September 30, 2020, which is expected to be recognized over a remaining average vesting period of 0.42 years as of September 30, 2020. The Company’s share-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
|  | (unaudited) |  |  | (unaudited) |
Research and development expense |  | $ | 570 |  |  | $ | 292 |  |  | $ | 748 |  |  | $ | 872 |
General and administrative expense |  |  | 942 |  |  |  | 558 |  |  |  | 1,604 |  |  |  | 1,761 |
There was a total of $23,852 and $2,103 unamortized share-based compensation expense for options, RSUs and Performance RSUs as of September 30, 2021 and September 30, 2020, respectively, which is expected to be recognized over a remaining average vesting period of 3.58 years and 0.65 years as of September 30, 2021 and September 30, 2020, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration